Tirzepatide vs Mounjaro: Same Drug? Brand, Zepbound
Mounjaro is a brand of tirzepatide, so the medicine inside is the same; Zepbound is the other tirzepatide brand. Mounjaro is approved for type 2 diabetes and heart risk.
- Ingredient
- tirzepatide
- Manufacturer
- Eli Lilly
- Other tirzepatide brands
- Zepbound
- Lowest tirzepatide self-pay
- $299 per month, Zepbound
Mounjaro and Zepbound at a glance
Side-by-side comparison of Mounjaro and Tirzepatide
Every brand label gives approved uses, forms, and price for that brand.
| Medicine | Ingredient | How it is taken | Approved for | Trial weight loss | Most common side effect | Self-pay from | List price |
|---|---|---|---|---|---|---|---|
| tirzepatide | Weekly injection | Type 2 diabetes and heart risk | Not listed | Nausea 18% vs 4% on placebo | Not listed | $1,112.16 per fill | |
| tirzepatide | Weekly injection | Weight loss and sleep apnea | 20.9% | Nausea 29% vs 8% on placebo | $299 per month | $499 to $1,086 per fill |
Sources are the FDA label (DailyMed) 1 2, pricinginfo.lilly.com 1 2, and TrumpRx.
Price and coverage compared
| Medicine | How you pay | Price |
|---|---|---|
| List price before insurance | $1,112.16 per fill | |
| Mounjaro Savings Card (insured) | from $25 for up to a 3-month fill | |
| Commercial plan that does not cover it | $499 per month | |
| List price before insurance | $499 to $1,086 per fill | |
| Zepbound Savings Program (insured) | from $25 for up to a 3-month fill | |
| Commercial plan that does not cover it | $299 per month | |
| Self-pay: LillyDirect vial or KwikPen 2.5 mg | $299 per month | |
| Self-pay: LillyDirect vial or KwikPen 5 mg | $399 per month | |
| Self-pay through LillyDirect: 7.5 mg up to 15 mg (refill within 45 days) | $449 per month | |
| Self-pay: Standard pricing if you do not refill within 45 days | per month, $499 covers $7.5 mg, and $699 covers $10 to $15 mg | |
| Self-pay via TrumpRx | $299 per month | |
| Medicare GLP-1 Bridge (Zepbound KwikPen, eligible Part D) | $50 per month |
Prices checked November 2026 (7)
pricinginfo.lilly.com 1 2, mounjaro.lilly.com, zepbound.lilly.com, Eli Lilly, TrumpRx, CMS.
Generic and compounded Tirzepatide versions
Shortage resolved. FDA confirmed this on December 19, 2024.
Sources: FDA.